Login / Signup

Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.

Alexandra Coomans de BrachèneAngela CastelaAnne Op de BeeckRaghavendra G MirmiraLorella MarselliPiero MarchettiCraig MasseWenyan MiaoSilvana LeitCarmella Evans-MolinaDecio L Eizirik
Published in: Diabetes, obesity & metabolism (2020)
The two TYK2 inhibitors tested inhibit the IFNα signalling pathway in human beta cells, decreasing its pro-inflammatory and pro-apoptotic effects without sensitizing the cells to viral infection. The preclinical findings could pave the way for future clinical trials with TYK2 inhibitors for the prevention and treatment of type 1 diabetes.
Keyphrases